Abstract: Provided are heterobifunctional degrader compounds that bind with cyclin dependent kinase 9 (CDK9) and E3 ubiquitin ligase. Also provided are methods of treating a subject for a CDK9-mediated disease by administering a therapeutically effective dose of a pharmaceutical composition including the heterobifunctional degrader.
Type:
Application
Filed:
November 4, 2021
Publication date:
June 12, 2025
Applicant:
KRONOS BIO, INC.
Inventors:
WES TROTTER, MARIUS POP, ZHIHUA MA, DAVID FREEMAN
Abstract: Certain imidazopyridines and pharmaceutical compositions thereof are provided herein. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of Syk activity, which comprises administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are provided. Also provided are methods for determining the presence or absence of Syk kinase in a sample.
Type:
Grant
Filed:
September 6, 2018
Date of Patent:
November 24, 2020
Assignee:
KRONOS BIO, INC.
Inventors:
Peter A. Blomgren, Kevin S. Currie, Jeffrey E. Kropf, Seung H. Lee, Scott A. Mitchell, Aaron C. Schmitt, Jianjun Xu, Zhongdong Zhao
Abstract: The present disclosure relates to compounds that are Syk inhibitors or pharmaceutically acceptable salts or co-crystals thereof, and pharmaceutical compositions thereof, and to their use in the treatment of various disease states, including cancer and inflammatory conditions.
Type:
Grant
Filed:
May 15, 2019
Date of Patent:
November 10, 2020
Assignee:
KRONOS BIO, INC.
Inventors:
Peter A. Blomgren, Kevin S. Currie, Jeffrey E. Kropf, Seung H. Lee, Jennifer R. Lo, Scott A. Mitchell, Aaron C. Schmitt, Sundaramoorthi Swaminathan, Jin-Ming Xiong, Jianjun Xu, Zhongdong Zhao
© 2025 Justia
